Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bellicum Pharma Comm (BLCM)

Bellicum Pharma Comm (BLCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,913
  • Shares Outstanding, K 5,060
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -112,480 K
  • 60-Month Beta 1.99
  • Price/Sales 4.71
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -3.29
  • Number of Estimates 1
  • High Estimate -3.29
  • Low Estimate -3.29
  • Prior Year -5.80
  • Growth Rate Est. (year over year) +43.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.64 +66.81%
on 09/04/20
8.19 -5.49%
on 09/15/20
+1.46 (+23.25%)
since 08/18/20
3-Month
4.64 +66.81%
on 09/04/20
9.15 -15.41%
on 06/19/20
-1.23 (-13.71%)
since 06/18/20
52-Week
3.32 +133.13%
on 03/16/20
27.90 -72.26%
on 01/17/20
-2.66 (-25.58%)
since 09/18/19

Most Recent Stories

More News
Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor...

BLCM : 7.74 (+12.17%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to three new employees consisting...

BLCM : 7.74 (+12.17%)
Shares of BLCM Up 33.9% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Bellicum Pharmac (NASDAQ:BLCM) on March 30th, 2020 at $4.89. In approximately 5 months, Bellicum Pharmac has returned 33.95% as of today's recent price of $6.55.

BLCM : 7.74 (+12.17%)
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

BLRX : 1.7500 (-0.57%)
PCRX : 60.77 (+1.47%)
BLCM : 7.74 (+12.17%)
ATNM : 10.33 (+7.94%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of...

BLCM : 7.74 (+12.17%)
Translate Bio Up on Vaccine Agreement Expansion With Sanofi

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

SNY : 52.44 (+0.71%)
TBIO : 14.78 (+0.20%)
BLCM : 7.74 (+12.17%)
ALPN : 8.67 (+4.08%)
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

JAZZ : 141.90 (+1.25%)
BLRX : 1.7500 (-0.57%)
BLCM : 7.74 (+12.17%)
ATNM : 10.33 (+7.94%)
Bellicum Pharmac Shares Up 55.4% Since SmarTrend's Buy Recommendation (BLCM)

SmarTrend identified an Uptrend for Bellicum Pharmac (NASDAQ:BLCM) on March 30th, 2020 at $4.89. In approximately 3 months, Bellicum Pharmac has returned 55.42% as of today's recent price of $7.60.

BLCM : 7.74 (+12.17%)
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T(R) for HER2+ Solid Tumors

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of...

BLCM : 7.74 (+12.17%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 6.12 (-1.29%)
ALIM : 5.70 (+1.60%)
ANVS : 5.33 (+3.50%)
AQB : 5.16 (+14.67%)
ARTL : 0.8500 (-3.41%)
AVLNF : 0.0515 (+5.10%)
BLCM : 7.74 (+12.17%)
NDRA : 0.7515 (-3.63%)
EFOI : 8.01 (+2.43%)
EQ : 6.41 (+0.63%)
EXROF : 0.8960 (+7.11%)
HL : 5.68 (-1.56%)
HSII : 21.79 (-0.50%)
HSDT : 0.4176 (-0.88%)
HGBL : 2.51 (-0.40%)
IPWR : 6.29 (+2.11%)
LINC : 6.37 (-4.21%)
MBII : 1.2100 (unch)
MLSS : 1.3700 (-8.67%)
MYSZ : 0.9700 (+2.11%)
NBEV : 1.8000 (unch)
ONCS : 4.50 (+4.41%)
OGEN : 0.7144 (+1.96%)
SFE : 5.55 (-2.46%)
SLS : 2.70 (+5.88%)
PIXY : 3.85 (-3.27%)
SGLB : 2.15 (-3.59%)
SOTK : 4.2400 (+11.58%)
TNXP : 0.9231 (-6.76%)
TGA : 0.4173 (-5.16%)
URG : 0.5458 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade BLCM with:

Business Summary

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product...

See More

Key Turning Points

2nd Resistance Point 8.79
1st Resistance Point 8.27
Last Price 7.74
1st Support Level 6.95
2nd Support Level 6.15

See More

52-Week High 27.90
Fibonacci 61.8% 18.51
Fibonacci 50% 15.61
Fibonacci 38.2% 12.71
Last Price 7.74
52-Week Low 3.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar